Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism

Li, Jia; Mao, QiuXian; He, Jingjun; She, HaoQing; Zhang, Zhi; Yin, Chunyue

doi:10.1186/s13287-017-0514-5

Cited by 102 publications

(76 citation statements)

References 54 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the acquisition number of human bone marrow mesenchymal stem cells (hBMSCs) cannot meet the huge demands for bone repair with invasive process, and the cellular activities are much influenced by the donor's age and health status, greatly restricting the clinical application . In contrast, MSCs from the Wharton's jelly of the neonatal umbilical cord, named human umbilical cord mesenchymal stem cells (hUCMSCs), possess a higher cell yield, rapid proliferation capacity, amounts of secreted cytokines related to cell migration, inflammation, immune regulation, angiogenesis (vascular endothelial growth factor [VEGF], insulin‐like growth factor‐1, transforming growth factor and platelet‐derived growth factor [PDGF]), neurogenic and wound healing processes . Above all, hUCMSCs do not express the major histocompatibility complex II (MHC II) and immunoregulatory factor B7 costimulatory molecules, which are responsible for the alloimmune response .…”

Section: Introductionmentioning

confidence: 99%

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

Rong

Zhou

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Objectives Mesenchymal stem cells (MSCs) based therapy for bone regeneration has been regarded as a promising method in the clinic. However, hBMSCs with invasive harvesting process and undesirable proliferation rate hinder the extensive usage. HUCMSCs of easier access and excellent performances provide an alternative for the fabrication of tissue‐engineered bone construct. Evidence suggested the osteogenesis ability of hUCMSCs was weaker than that of hBMSCs. To address this issue, a co‐culture strategy of osteogenically and angiogenically induced hUCMSCs has been proposed since thorough vascularization facilitates the blood‐borne nutrition and oxygen to transport in the scaffold, synergistically expediting the process of ossification. Materials and methods Herein, we used osteogenic‐ and angiogenic‐differentiated hUCMSCs for co‐culture in screened culture medium to elevate the osteogenic capacity with in vitro studies and finally coupled with 3D TCP scaffold to repair rat's critical‐sized calvarial bone defect. By dual‐directional induction, hUCMSCs could differentiate into osteoblasts and endothelial cells, respectively. To optimize the co‐culture condition, gradient ratios of dual‐directional differentiated hUCMSCs co‐cultured under different medium were studied to determine the appropriate condition. Results It revealed that the osteogenic‐ and angiogenic‐induced hUCMSCs mixed with the ratio of 3:1 co‐cultured in the mixed medium of osteogenic induction medium to endothelial cell induction medium of 3:1 possessed more mineralization nodules. Similarly, ALP and osteogenesis/angiogenesis‐related genes expressions were relatively higher. Further evidence of bone defect repair with 3D printed TCP of 3:1 group exhibited better restoration outcomes. Conclusions Our work demonstrated a favourable and convenient approach of dual‐directional differentiated hUCMSCs co‐culture to improve the osteogenesis, establishing a novel way to fabricate tissue‐engineered bone graft with 3D TCP for large bone defect augmentation.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

Rong

Zhou

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…Previous study indicated that human umbilical cord mesenchymal stem cells improve the ovarian function by paracrine mechanism (Li et al, 2017). Recently, study results have demonstrated that EGF released from human placental mesenchymal stem cells could restore ovarian function through regulating oxidative stress pathway (NRF/HO-1) (Ding et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Human Amniotic Fluid Mesenchymal Stem Cells Improve Ovarian Function During Physiological Aging by Resisting DNA Damage

et al. 2020

View full text Add to dashboard Cite

Many studies have shown that mesenchymal stem cells have the ability to restore function in models of premature ovarian insufficiency disease, but few studies have used stem cells in the treatment of ovarian physiologic aging (OPA). This experimental study was designed to determine whether human amniotic fluid mesenchymal stem cells (hAFMSCs) have the ability to recover ovarian vitality and to determine how they function in this process. Mice (12-14 months old) were used in this study, and young fertile female mice (3-5 months old) were the control group. Ovarian markers for four stages of folliculogenesis and DNA damage genes were tested by qPCR and western blot. hAFMSCs were used to treat an OPA mouse model, and the animals treated with hAFMSCs displayed better therapeutic activity in terms of the function of the mouse ovary, increasing follicle numbers and improving hormone levels. In addition, our results demonstrated that the marker expression level in ovarian granular cells from patients with OPA was elevated significantly after hAFMSC treatment. In addition, the proliferation activity was improved, and apoptosis was dramatically inhibited after hAFMSCs were cocultured with hGCs from OPA patients. Finally, in this study, hAFMSCs were shown to increase the mRNA and protein expression levels of ovarian markers at four stages of folliculogenesis and to inhibit the expression of DNA damage genes. These works have provided insight into the view that hAFMSCs play an integral role in resisting OPA. Moreover, our present study demonstrates that hAMSCs recover ovarian function in OPA by restoring the expression of DNA damage genes.

show abstract

“…Ding C et al [11] used 12-to 14-month-old female mice as ageing models. Jia Li et al [10] used 12-to 14-month-old female SD rats, and the oestrous cycles were observed to determine cycle disorder as a model. Induced ageing models mainly employ superovulation to accelerate ovarian ageing.…”

Section: Transcription Levels Of the Apoptosis-related Genesmentioning

confidence: 99%

“…In many studies, the stem cells used to treat ovarian ageing are human umbilical cord mesenchymal stem cells [10], human amniotic mesenchymal stem cells [11], or human fat-derived mesenchymal stem cells [15]. No one has used a mouse model and adopted mouse umbilical cord mesenchymal stem cells (mUCMSCs).…”

Section: Mucmscs For Cell Transplantationmentioning

confidence: 99%

“…Many studies have used mesenchymal stem cells to treat ovarian ageing. Li J et al [10] used human umbilical cord mesenchymal stem cells (hUCMSCs) to treat naturally ageing rats. The results showed that hUCMSCs can secrete hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) and can also promote the expression of the above three factors, thereby improving ovarian reserve function and mediating resistance to ovarian ageing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanism and Effect of UCMSCS on Ovarian Structure and Function in Naturally Ageing C57 Mice

X¹,

Zhang²,

Yao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The ovary is the core reproductive organ of a woman and is of great significance for maintaining normal functioning of the reproductive system and the stability of the endocrine system. With an increase in age, the ovaries begin to age, and ovarian ageing will cause a decline in fertility. Methods: Ageing C57 mice were used to explore the mechanism by which mouse umbilical cord mesenchymal stem cells (mUCMSCs) promote the antioxidant repair of granulocytes (mGCs). The ovarian volume in C57 mice, which were routinely reared to 18 months, decreased, and the follicles at all levels disappeared. All statistical analyses were performed using SPSS 21.0 statistical software. P <0.05 was considered to indicate a significant difference. Results: After mUCMSC transplantation, the mouse ovaries increased in size, follicles at various levels were seen in the cortex, and sinus follicle counts increased, indicating that mUCMSCs have a curative effect on ovarian ageing. Conclusions: mUCMSCs downregulated the expression of apoptosis-related genes (Bax, Caspase-3), upregulated the expression of SOD2 and the peroxidase gene PRDX IV, and reduced the granulocyte apoptosis rate and ROS level. Co-cultivation with mUCMSCs can increase antioxidative stress in mGCs and reduce mGC apoptosis.

show abstract

Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism

Cited by 102 publications

References 54 publications

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

A novel method to improve the osteogenesis capacity of hUCMSCs with dual‐directional pre‐induction under screened co‐culture conditions

Human Amniotic Fluid Mesenchymal Stem Cells Improve Ovarian Function During Physiological Aging by Resisting DNA Damage

Mechanism and Effect of UCMSCS on Ovarian Structure and Function in Naturally Ageing C57 Mice

Contact Info

Product

Resources

About